The SLYDIV project has delivered several scientific and technological advances that significantly extend the current state of the art in bacterial cell envelope biology, structural microbiology, and bioengineering.
A key achievement was the complete atomic-level characterization of the Sap S-layer protein from Bacillus anthracis, revealing a novel conformational switch and four stabilizing interdomain interfaces. These findings provide a mechanistic framework for S-layer assembly and offer new molecular targets for antimicrobial development, particularly relevant in the context of antimicrobial resistance and biosecurity.
In Corynebacterium glutamicum, I solved the PS2 S-layer structure at 2.5 Å resolution and discovered that its assembly is spatially restricted to the cell poles, coordinated with the elongasome. This was the first demonstration of polar S-layer biogenesis and challenges the prevailing model of mid-cell insertion. I also developed a modular S-layer engineering platform using SpyTag/SpyCatcher technology, enabling programmable surface display in a GRAS industrial host. This innovation opens new avenues for applications in vaccine delivery, biosensing, and biocatalysis.
In addition to the original project objectives, I contributed to a collaborative study that led to the discovery and structural characterization of a novel class of protein nanofibers, A-ENA (alpha-helical endospore appendages) produced by Bacillus thuringiensis. These fibers form a chemically and physically robust extracellular matrix that clusters spores and parasporal bodies (PSBs), enhancing the insecticidal efficacy of this biopesticide. I demonstrated that A-ENA acts as a virulence factor and that its recombinant production in E. coli enables non-GMO functionalization of other Bt strains. This work introduces a new bioengineering tool for improving the performance of biological pest control agents and contributes to sustainable agriculture and integrated pest management strategies.
These innovations have led to two patent applications:
• WO2025/046122: This patent covers the design, production, and application of A-ENA nanofibers as highly stable, self-assembling bionanomaterials. It includes methods for recombinant production and their use in modifying bacterial endospores and enhancing their activity or pathogenicity.
• EP25162107.4 (priority filing): This application focuses on the use of A-ENA nanofibers to enhance the pesticidal activity of Bt strains, offering a non-GMO strategy to improve the efficacy of biocontrol agents.
Potential Impacts and Future Needs
• Further Research: Continued investigation into the regulation, secretion, and host interactions of S-layers and A-ENA fibers will be essential to fully exploit their therapeutic and biotechnological potential.
• Demonstration and Scale-Up: The PS2 display platform and A-ENA-based biofilm engineering should be validated in industrial and agricultural settings to assess scalability, robustness, and regulatory compliance.
• Commercialisation and IPR: The A-ENA nanofiber technology is protected through patent filings. Further support from technology transfer offices will be needed to explore licensing opportunities and partnerships with biotech and agri-tech companies.
• Internationalisation: The project has already fostered international collaborations and is well-positioned to expand into global networks focused on antimicrobial innovation, synthetic biology, and sustainable agriculture.
• Regulatory and Standardisation Frameworks: For therapeutic and agricultural applications, early engagement with regulatory bodies will be crucial to define safety, efficacy, and environmental impact standards.
In summary, the SLYDIV project has not only fulfilled its original objectives but also generated high-impact, patentable innovations through interdisciplinary collaboration. These outcomes position the project at the forefront of microbial structural biology and synthetic biology, with clear pathways toward societal, environmental, and industrial impact.